Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps
Political momentum and funding for combatting antimicrobial resistance (AMR) continues to build. Numerous major international and national initiatives aimed at financially incentivising the research and development (R&D) of antibiotics have been implemented. However, it remains unclear how to ef...
Gespeichert in:
| Veröffentlicht in: | Journal of antibiotics Jg. 70; H. 12; S. 1087 - 1096 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
London
Nature Publishing Group UK
01.12.2017
Nature Publishing Group |
| Schlagworte: | |
| ISSN: | 0021-8820, 1881-1469, 1881-1469 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Political momentum and funding for combatting antimicrobial resistance (AMR) continues to build. Numerous major international and national initiatives aimed at financially incentivising the research and development (R&D) of antibiotics have been implemented. However, it remains unclear how to effectively strengthen the current set of incentive programmes to further accelerate antibiotic innovation. Based on a literature review and expert input, this study first identifies and assesses the major international, European Union, US and UK antibiotic R&D funding programmes. These programmes are then evaluated across market and public health criteria necessary for comprehensively improving the antibiotic market. The current set of incentive programmes are an important initial step to improving the economic feasibility of antibiotic development. However, there appears to be a lack of global coordination across all initiatives, which risks duplicating efforts, leaving funding gaps in the value chain and overlooking important AMR goals. This study finds that incentive programmes are overly committed to early-stage push funding of basic science and preclinical research, while there is limited late-stage push funding of clinical development. Moreover, there are almost no pull incentives to facilitate transition of antibiotic products from early clinical phases to commercialisation, focus developer concentration on the highest priority antibiotics and attract large pharmaceutical companies to invest in the market. Finally, it seems that antibiotic sustainability and patient access requirements are poorly integrated into the array of incentive mechanisms. |
|---|---|
| AbstractList | Political momentum and funding for combatting antimicrobial resistance (AMR) continues to build. Numerous major international and national initiatives aimed at financially incentivising the research and development (R&D) of antibiotics have been implemented. However, it remains unclear how to effectively strengthen the current set of incentive programmes to further accelerate antibiotic innovation. Based on a literature review and expert input, this study first identifies and assesses the major international, European Union, US and UK antibiotic R&D funding programmes. These programmes are then evaluated across market and public health criteria necessary for comprehensively improving the antibiotic market. The current set of incentive programmes are an important initial step to improving the economic feasibility of antibiotic development. However, there appears to be a lack of global coordination across all initiatives, which risks duplicating efforts, leaving funding gaps in the value chain and overlooking important AMR goals. This study finds that incentive programmes are overly committed to early-stage push funding of basic science and preclinical research, while there is limited late-stage push funding of clinical development. Moreover, there are almost no pull incentives to facilitate transition of antibiotic products from early clinical phases to commercialisation, focus developer concentration on the highest priority antibiotics and attract large pharmaceutical companies to invest in the market. Finally, it seems that antibiotic sustainability and patient access requirements are poorly integrated into the array of incentive mechanisms. Political momentum and funding for combatting antimicrobial resistance (AMR) continues to build. Numerous major international and national initiatives aimed at financially incentivising the research and development (R&D) of antibiotics have been implemented. However, it remains unclear how to effectively strengthen the current set of incentive programmes to further accelerate antibiotic innovation. Based on a literature review and expert input, this study first identifies and assesses the major international, European Union, US and UK antibiotic R&D funding programmes. These programmes are then evaluated across market and public health criteria necessary for comprehensively improving the antibiotic market. The current set of incentive programmes are an important initial step to improving the economic feasibility of antibiotic development. However, there appears to be a lack of global coordination across all initiatives, which risks duplicating efforts, leaving funding gaps in the value chain and overlooking important AMR goals. This study finds that incentive programmes are overly committed to early-stage push funding of basic science and preclinical research, while there is limited late-stage push funding of clinical development. Moreover, there are almost no pull incentives to facilitate transition of antibiotic products from early clinical phases to commercialisation, focus developer concentration on the highest priority antibiotics and attract large pharmaceutical companies to invest in the market. Finally, it seems that antibiotic sustainability and patient access requirements are poorly integrated into the array of incentive mechanisms.Political momentum and funding for combatting antimicrobial resistance (AMR) continues to build. Numerous major international and national initiatives aimed at financially incentivising the research and development (R&D) of antibiotics have been implemented. However, it remains unclear how to effectively strengthen the current set of incentive programmes to further accelerate antibiotic innovation. Based on a literature review and expert input, this study first identifies and assesses the major international, European Union, US and UK antibiotic R&D funding programmes. These programmes are then evaluated across market and public health criteria necessary for comprehensively improving the antibiotic market. The current set of incentive programmes are an important initial step to improving the economic feasibility of antibiotic development. However, there appears to be a lack of global coordination across all initiatives, which risks duplicating efforts, leaving funding gaps in the value chain and overlooking important AMR goals. This study finds that incentive programmes are overly committed to early-stage push funding of basic science and preclinical research, while there is limited late-stage push funding of clinical development. Moreover, there are almost no pull incentives to facilitate transition of antibiotic products from early clinical phases to commercialisation, focus developer concentration on the highest priority antibiotics and attract large pharmaceutical companies to invest in the market. Finally, it seems that antibiotic sustainability and patient access requirements are poorly integrated into the array of incentive mechanisms. |
| Author | Simpkin, Victoria L Kelly, Ruth Mossialos, Elias Renwick, Matthew J |
| Author_xml | – sequence: 1 givenname: Victoria L surname: Simpkin fullname: Simpkin, Victoria L organization: Department of Health Policy, London School of Economics and Political Science – sequence: 2 givenname: Matthew J surname: Renwick fullname: Renwick, Matthew J organization: Department of Health Policy, London School of Economics and Political Science – sequence: 3 givenname: Ruth surname: Kelly fullname: Kelly, Ruth organization: Department of Health Policy, London School of Economics and Political Science – sequence: 4 givenname: Elias surname: Mossialos fullname: Mossialos, Elias email: E.A.MOSSIALOS@LSE.AC.UK organization: Department of Health Policy, London School of Economics and Political Science, Institute of Global Health Innovation, Imperial College London |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29089600$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkc1r3DAUxEVJaTZpT70XQy-Fxls9-UNSD4UQ-hEI9JK7kOVnR8YruZJtmv8-2mxS0pCTBO83wwxzQo6cd0jIe6BboIX4Mugto8C3wMpXZANCQA5lLY_IhlIGuRCMHpOTGAdKC15w8YYcM0mFrCndkOHSGXSzXW20rs-sc37Vs_UufTOdDo31szVZG5Y-a200fsVwmy5t1uKKo592Sf41m4LvA8Z4lpkbPY7oeoz3lMO_cxZnnOJb8rrTY8R3D-8puf7x_friV371--flxflVbqqinvMWWs0NNk2JHdRlxwwFWjZc1C1rTce11B2VtDF1yQBqENzIquOiKHSJDItT8u1gOy3NDtt9u6BHNQW70-FWeW3V_xdnb1TvV1Xxsq4kJINPDwbB_1kwzmqXeuM4aod-iQpkJaqSUV4k9OMzdPBLcKldorjgFCSTifrwNNG_KI8rJAAOgAk-xoCdMna-XyEFtKMCqvZLq0Gr_dIqLZ00n59pHm1fps8OdExU2iY8CfoCfgdFSbpq |
| CitedBy_id | crossref_primary_10_1016_j_cdc_2019_100276 crossref_primary_10_1016_j_socscimed_2022_114818 crossref_primary_10_1016_j_clp_2019_02_015 crossref_primary_10_1016_j_ijid_2019_10_005 crossref_primary_10_1002_advs_201901872 crossref_primary_10_2217_fmb_2019_0227 crossref_primary_10_1089_adt_2022_038 crossref_primary_10_3390_ma11020321 crossref_primary_10_1016_j_ijantimicag_2024_107216 crossref_primary_10_1136_bmjgh_2021_008181 crossref_primary_10_3390_app13074238 crossref_primary_10_1016_j_addr_2022_114302 crossref_primary_10_1017_ash_2025_38 crossref_primary_10_1186_s13568_021_01251_3 crossref_primary_10_3390_antibiotics7030061 crossref_primary_10_1016_j_sjbs_2021_05_033 crossref_primary_10_1007_s13205_021_02891_9 crossref_primary_10_1007_s40290_025_00572_z crossref_primary_10_3390_antibiotics11020182 crossref_primary_10_1038_s41429_020_0300_y crossref_primary_10_1016_j_diagmicrobio_2019_02_019 crossref_primary_10_3390_molecules27062002 crossref_primary_10_1016_j_genrep_2021_101393 crossref_primary_10_3390_microorganisms13030557 crossref_primary_10_1093_infdis_jiz134 crossref_primary_10_1080_17460441_2018_1515908 crossref_primary_10_1007_s00449_024_03091_4 crossref_primary_10_1016_j_addr_2021_05_032 crossref_primary_10_1007_s11274_022_03285_6 crossref_primary_10_1002_cmdc_202300505 crossref_primary_10_1038_s41598_020_60968_6 crossref_primary_10_1039_D0BM01865A crossref_primary_10_3390_pharmaceutics16121568 crossref_primary_10_1016_j_jphotochemrev_2021_100454 crossref_primary_10_3390_v10070345 crossref_primary_10_1038_s41570_021_00313_1 crossref_primary_10_1080_1040841X_2023_2197491 crossref_primary_10_1080_14787210_2020_1798228 crossref_primary_10_1016_j_bmc_2020_115776 crossref_primary_10_1021_acsinfecdis_5c00298 crossref_primary_10_3390_ijerph15122758 crossref_primary_10_3390_molecules26133800 crossref_primary_10_1039_C8ME00051D crossref_primary_10_3390_antibiotics10060614 crossref_primary_10_1016_S1473_3099_19_30415_3 crossref_primary_10_1016_j_bmcl_2019_03_029 crossref_primary_10_1007_s11172_024_4466_5 crossref_primary_10_1007_s40319_018_00782_w crossref_primary_10_1186_s12992_023_00930_z crossref_primary_10_2174_0929867330666230123143458 crossref_primary_10_3390_molecules23061476 crossref_primary_10_1038_s41598_019_39387_9 crossref_primary_10_1038_s41429_021_00414_5 crossref_primary_10_1016_j_molstruc_2021_131380 crossref_primary_10_3390_ijms21155460 crossref_primary_10_1128_AAC_00878_21 crossref_primary_10_1128_CMR_00066_18 crossref_primary_10_1016_j_jiec_2024_07_039 crossref_primary_10_1016_j_ejmech_2021_113200 crossref_primary_10_1002_ppsc_202000253 crossref_primary_10_1016_j_jprot_2018_11_006 crossref_primary_10_2147_IDR_S284331 crossref_primary_10_3390_antibiotics10091065 crossref_primary_10_1016_j_sjbs_2022_01_045 crossref_primary_10_1016_j_drudis_2020_10_011 crossref_primary_10_1016_j_jtbi_2019_110109 crossref_primary_10_1016_j_ejmech_2019_111671 crossref_primary_10_3390_antibiotics8040251 crossref_primary_10_1093_femsyr_foaa023 crossref_primary_10_1002_ps_6357 crossref_primary_10_1038_s41429_024_00788_2 crossref_primary_10_2147_IDR_S287792 crossref_primary_10_1099_jmm_0_001965 crossref_primary_10_3762_bjoc_14_267 crossref_primary_10_1371_journal_pone_0269021 crossref_primary_10_1016_j_heliyon_2021_e08469 crossref_primary_10_3389_fpubh_2020_00161 crossref_primary_10_1002_cbdv_202000907 crossref_primary_10_1080_2331186X_2024_2387951 crossref_primary_10_1186_s13756_019_0654_8 crossref_primary_10_2166_wh_2023_141 crossref_primary_10_1371_journal_pcbi_1009870 crossref_primary_10_1016_S1473_3099_19_30552_3 crossref_primary_10_1016_j_ejmech_2020_112533 crossref_primary_10_1016_j_giec_2020_06_004 crossref_primary_10_3390_microbiolres12010013 crossref_primary_10_1038_s41594_021_00708_0 crossref_primary_10_1002_slct_202402472 crossref_primary_10_1007_s10728_020_00393_y crossref_primary_10_1038_s41598_024_82056_9 crossref_primary_10_1371_journal_pone_0223932 crossref_primary_10_1016_j_ejmech_2020_113002 crossref_primary_10_3390_molecules27165167 crossref_primary_10_1016_j_ccr_2022_214481 crossref_primary_10_1080_1040841X_2018_1538934 crossref_primary_10_1093_scipol_scae002 crossref_primary_10_1016_j_molstruc_2025_142953 crossref_primary_10_3389_fmicb_2019_01671 crossref_primary_10_1016_j_jmb_2019_06_033 crossref_primary_10_1007_s10728_019_00388_4 crossref_primary_10_1093_cid_ciz089 crossref_primary_10_1007_s10989_018_9793_7 crossref_primary_10_1093_heapro_daaf120 crossref_primary_10_7861_fhj_2021_0087 crossref_primary_10_1016_j_bmcl_2018_06_003 crossref_primary_10_1016_j_bioorg_2021_104786 crossref_primary_10_1002_mbo3_1260 crossref_primary_10_1016_j_mib_2022_102228 crossref_primary_10_3390_v12020133 crossref_primary_10_31201_ijhmt_1598478 crossref_primary_10_1016_j_jgar_2022_02_006 crossref_primary_10_1093_cid_ciz1132 crossref_primary_10_1016_j_jhazmat_2019_121821 crossref_primary_10_1111_1468_0009_70050 crossref_primary_10_1017_ice_2018_252 crossref_primary_10_1016_j_inoche_2022_109779 crossref_primary_10_1002_wmh3_440 crossref_primary_10_1016_j_nxbio_2025_100003 crossref_primary_10_1080_14656566_2018_1534957 crossref_primary_10_1080_20016689_2019_1583536 crossref_primary_10_3390_antibiotics7040085 crossref_primary_10_3390_molecules24152815 crossref_primary_10_1016_j_jgar_2023_03_006 crossref_primary_10_1080_13543776_2025_2491382 crossref_primary_10_1097_ID9_0000000000000112 crossref_primary_10_2174_1570180819666220929143234 crossref_primary_10_1108_IJHG_12_2019_0083 crossref_primary_10_1186_s43094_025_00876_6 crossref_primary_10_12688_wellcomeopenres_16847_1 crossref_primary_10_1116_6_0002515 crossref_primary_10_3390_biology12010101 crossref_primary_10_1513_AnnalsATS_202102_209ST crossref_primary_10_3389_fbioe_2021_669728 crossref_primary_10_1128_AAC_01208_20 crossref_primary_10_3389_fcimb_2021_684515 crossref_primary_10_7759_cureus_36013 crossref_primary_10_1039_D0BM01160F crossref_primary_10_3390_antibiotics12061065 crossref_primary_10_1007_s12551_023_01066_5 crossref_primary_10_1016_j_molstruc_2023_137115 crossref_primary_10_1016_j_cmi_2022_11_027 |
| Cites_doi | 10.1089/hs.2014.0081 10.1016/S1473-3099(08)70018-5 10.1186/s12992-016-0147-y 10.2471/BLT.15.153171 10.1038/ja.2015.98 10.3233/JRS-2005-349 10.1038/nrd.2016.155 10.1186/cc13948 10.1016/j.ijid.2016.09.016 10.1016/S1473-3099(15)00407-7 10.1093/jac/dkv339 10.1016/S1473-3099(15)00500-9 10.1016/S1473-3099(12)70293-1 10.1186/1744-8603-9-58 10.1038/ja.2013.86 10.1377/hlthaff.2014.1003 10.1016/S1473-3099(15)00350-3 10.1089/hs.2015.0034 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2017 Copyright Nature Publishing Group Dec 2017 Copyright © 2017 The Author(s) 2017 The Author(s) |
| Copyright_xml | – notice: The Author(s) 2017 – notice: Copyright Nature Publishing Group Dec 2017 – notice: Copyright © 2017 The Author(s) 2017 The Author(s) |
| DBID | C6C AAYXX CITATION NPM 3V. 7QL 7T5 7X7 7XB 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M2P M7P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 5PM |
| DOI | 10.1038/ja.2017.124 |
| DatabaseName | Springer Nature OA Free Journals CrossRef PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Immunology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Journals Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability (subscription) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Database AUTh Library subscriptions: ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection PML(ProQuest Medical Library) Science Database Biological Science Database ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Health & Medical Research Collection Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic ProQuest Central Student |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology Public Health |
| DocumentTitleAlternate | Incentivising antibiotic discovery and development |
| EISSN | 1881-1469 |
| EndPage | 1096 |
| ExternalDocumentID | PMC5746591 29089600 10_1038_ja_2017_124 |
| Genre | Journal Article Review |
| GroupedDBID | --- -Q- -~X .55 .GJ 0R~ 29J 2WC 39C 3O- 3V. 4.4 406 41~ 53G 5GY 70F 7X7 88E 88I 8FI 8FJ AACDK AANZL AASML AATNV AAZLF ABAKF ABAWZ ABJNI ABUWG ABZZP ACAOD ACGFS ACKTT ACRQY ACZOJ ADBBV ADHDB AEFQL AEJRE AEMSY AENEX AEUYN AEVLU AEXYK AFBBN AFKRA AFSHS AGAYW AGHAI AGQEE AHMBA AHSBF AIGIU AILAN AJRNO ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS AMYLF AXYYD AZQEC BAWUL BBNVY BENPR BHPHI BKKNO BPHCQ BVXVI C6C CCPQU DIK DNIVK DPUIP DU5 DWQXO EBLON EBS EE. EIOEI EJD EMB EMOBN F5P FDQFY FERAY FIGPU FIZPM FSGXE FYUFA GNUQQ HCIFZ HMCUK HZ~ IWAJR JSF JSH JSO JZLTJ KQ8 M1P M2P M7P NAO NQJWS O9- OK1 P6G PKN PQQKQ PROAC PSQYO RJT RNT RNTTT ROL RZJ SNX SNYQT SOHCF SRMVM SV3 SWTZT TAOOD TBHMF TDRGL TKC TR2 TSG UKHRP UPT W2D X7J X7M YQT ZGI ZXP AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC AEZWR AFDZB AFFHD AFHIU AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB PPXIY PQGLB SOJ NPM 7QL 7T5 7XB 8FE 8FH 8FK C1K H94 K9. LK8 PKEHL PQEST PQUKI PRINS Q9U 7X8 5PM |
| ID | FETCH-LOGICAL-c536t-d1da7cebb4ef164f2c0104b786d2dcf7a9af090bc642116187c95f7833a4e2e3 |
| IEDL.DBID | M7P |
| ISICitedReferencesCount | 161 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000418362200002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0021-8820 1881-1469 |
| IngestDate | Tue Nov 04 01:56:33 EST 2025 Sun Nov 09 12:42:42 EST 2025 Sat Nov 29 14:48:47 EST 2025 Wed Feb 19 02:42:53 EST 2025 Sat Nov 29 07:47:44 EST 2025 Tue Nov 18 21:56:23 EST 2025 Fri Feb 21 02:37:17 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Language | English |
| License | This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c536t-d1da7cebb4ef164f2c0104b786d2dcf7a9af090bc642116187c95f7833a4e2e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC5746591 |
| PMID | 29089600 |
| PQID | 1978701929 |
| PQPubID | 2041950 |
| PageCount | 10 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5746591 proquest_miscellaneous_1958542073 proquest_journals_1978701929 pubmed_primary_29089600 crossref_citationtrail_10_1038_ja_2017_124 crossref_primary_10_1038_ja_2017_124 springer_journals_10_1038_ja_2017_124 |
| PublicationCentury | 2000 |
| PublicationDate | 2017-12-01 |
| PublicationDateYYYYMMDD | 2017-12-01 |
| PublicationDate_xml | – month: 12 year: 2017 text: 2017-12-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: Japan – name: Tokyo |
| PublicationSubtitle | Official journal of the Society for Actinomycetes, Japan |
| PublicationTitle | Journal of antibiotics |
| PublicationTitleAbbrev | J Antibiot |
| PublicationTitleAlternate | J Antibiot (Tokyo) |
| PublicationYear | 2017 |
| Publisher | Nature Publishing Group UK Nature Publishing Group |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group |
| References | European Investment Bank. InnovFin Infectious Disease, http://www.eib.org/attachments/documents/innovfin_infectious_diseases_flysheet_en.pdf (2015). KostyanevTThe innovative medicines initiative's new drugs for bad bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistanceJ. Antimicrob. Chemother.2016712902951:CAS:528:DC%2BC28Xjs1Ohsr8%3D10.1093/jac/dkv33926568581 UK-China ties flourish at 2016 High Level People to People Dialogue, https://www.gov.uk/government/news/uk-china-ties-flourish-at-2016-high-level-people-to-people-dialogue (2016). HoffmanSJStrategies for achieving global collective action on antimicrobial resistanceBull. World Health Organ20159386787610.2471/BLT.15.153171266684394669731 SpellbergBThe future of antibioticsCrit. Care20141822810.1186/cc13948250439624075146 Political Declaration of the high-level meeting of the General Assembly on antimicrobial resistance http://www.un.org/ga/search/view_doc.asp?symbol=A/71/L.2&referer=/english/&Lang=E (2016). KellyRZoubianeGWalshDWardRGoossensHPublic funding for research on antibacterial resistance in the JPIAMR countries, the European Commission, and related European Union agencies: a systematic observational analysisLancet Infect. Dis.20161643144010.1016/S1473-3099(15)00350-3267085244802226 BillingtonJKThe ABCs of the US Broad Spectrum Antimicrobials Program: antibiotics, biosecurity, and congressHealth Secur.20151334935410.1089/hs.2015.0034265693794685490 Office of the Assistant Secretary of Preparedness and Response. HHS forms strategic alliance to develop new antibiotics approach provides a pipeline of new drugs rather than a single medical countermeasure. US Department of Health and Human Services, http://www.phe.gov/Preparedness/news/Pages/strategic-alliance-130522.aspx (2013). European and Developing Countries Clinical Trials Partnership. Annual Report 2014, The Hague NL, 1–76, http://www.edctp.org/annualreport2014/EDCTP_Annual_Report_2014_-_EN.pdf (2014). KostyanevTBontenMJO'BrienSGoossensHInnovative medicines initiative and antibiotic resistanceLancet Infect. Dis.2015151373137510.1016/S1473-3099(15)00407-726607115 CARB-X, http://www.carb-x.org (2017). MonnetDLAntibiotic development and the changing role of the pharmaceutical industryInt. J. Risk Saf. Med.200517133145 The Review on Antimicrobial Resistance. Securing new drugs for future generations: the pipeline of antibiotics, London UK, 1–44, https://amr-review.org/sites/default/files/SECURING%20NEW%20DRUGS%20FOR%20FUTURE%20GENERATIONS%20FINAL%20WEB_0.pdf (2015). ChopraITreatment of health-care-associated infections caused by Gram-negative bacteria: a consensus statementLancet Infect. Dis.2008813313910.1016/S1473-3099(08)70018-518222164 US Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013, Atlanta US, 1–114, https://www.cdc.gov/drugresistance/threat-report-2013/index.html (2013). MossialosEEdwardsMCBerensonSGemmill-ToyamaJBroganMDPolicies and Incentives for Promoting Innovation in Antibiotic Research2010World Health Organisation EC. Antimicrobial drug resistance https://ec.europa.eu/research/health/index.cfm?pg=area&areaname=amdr (2017). Drive-AB Official Website, http://drive-ab.eu/. Renwick, M. J., Simpkin, V. & Mossialos, E. Targeting innovation in antibiotic drug discovery and development: the need for a one-health, one-Europe, one-world framwork. European Observatory on Health Systems and Policies, London, UK, Health Policy Series No. 45, 1–133, ISBN 9789289050401 (2016). Antibiotics Currently in Clinical Development http://www.pewtrusts.org/~/media/assets/2017/05/antibiotics-currently-in-clinical-development-03-2017.pdf?la=en (2017). National Institute for Health Research. Antimicrobial resistance http://www.nihr.ac.uk/research-and-impact/research-priorities/antimicrobial-resistance.htm. FerraroJSTowseAMestre-FerrandizJIncentives for New Drugs to Tackle Anti-Microbial Resistance2017Office of Health Economics KesselheimAOuttersonKImproving antibiotic markets for long term sustainabilityYale J. Health Pol. Law Ethics201311101168 BroganDMMossialosEA critical analysis of the review on antimicrobial resistance report and the infectious disease financing facilityGlobal Health201612810.1186/s12992-016-0147-y270008474802890 WHO Global Priority List of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics 1–7 World Health Organisation, (2017). BroganDMMossialosEIncentives for new antibiotics: the Options Market for Antibiotics (OMA) modelGlobal Health201395810.1186/1744-8603-9-58241998354226193 RenwickMJBroganDMMossialosEA systematic review and critical assessment of incentive strategies for discovery and development of novel antibioticsJ. Antibiot. (Tokyo)20166973881:CAS:528:DC%2BC28Xjt1Oku78%3D10.1038/ja.2015.98 First Joint Call: innovative approaches to address antibacterial resistance http://www.jpiamr.eu/activities/joint-calls/first-joint-callresult/ (2014). RexJHOuttersonKAntibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approachLancet Infect. Dis.20161650050510.1016/S1473-3099(15)00500-927036356 The Boston Consulting Group. Breaking through the wall: enhancing research and development of antibiotics in science and industry, Berlin DE, 1–84, https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/5_Publikationen/Gesundheit/Berichte/GUARD_Follow_Up_Report_Full_Report_final.pdf (2017). Interagency Coordination Group on Antimicrobial Resistance. https://www.un.org/sg/en/content/sg/personnel-appointments/2017-03-17/interagency-coordination-group-antimicrobial-resistance (2017). CARB-X.. CARB-X injects up to $48 million to accelerate first powered by CARB-X portfolio of drug discovery and development projects to tackle antibiotic resistance, http://www.carb-x.org/press (2017). The Review on Antimicrobial Resistance. Tackling a global health crisis: initial steps, London UK, 1–22, https://amr-review.org/sites/default/files/Report-52.15.pdf (2015). Pew Charitable Trusts. GAIN: how a new law is stimulating the development of antibiotics http://www.pewtrusts.org/en/research-and-analysis/issue-briefs/2013/11/07/gain-how-a-new-law-is-stimulating-the-development-of-antibiotics/ (2013). Pew Charitable Trusts. LPAD: a regulatory pathway to develop antibiotics and fight drug-resistant infections http://www.pewtrusts.org/en/research-and-analysis/q-and-a/2015/06/lpad-a-regulatory-pathway-to-develop-antibiotics-and-fight-drug-resistant-infections (2015). OuttersonKPowersJHDanielGWMcClellanMBRepairing the broken market for antibiotic innovationHealth Aff. (Millwood)20153427728510.1377/hlthaff.2014.1003 Global Antibiotic Research & Development Partnership (GARDP), http://www.dndi.org/diseases-projects/gardp/ (2017). EichbergMJPublic funding of clinical-stage antibiotic development in the United States and European UnionHealth Secur.20151315616510.1089/hs.2014.0081260428594486734 Joint Programming Initiative on Antimicrobial Resistance, http://www.jpiamr.eu (2017). EC. Better use of antibiotics-1 million euros, http://ec.europa.eu/research/horizonprize/index.cfm?prize=better-use-antibiotics (2017). SternSC.SFrankenLVollerSRentmeisterHGroschBA Call for Concerted Action on Antibiotics Research and evelopment2017The Boston Consulting Group, Berlin MRC Tackling AMR-a cross-council initiative. https://www.mrc.ac.uk/research/initiatives/antimicrobial-resistance/tackling-amr-a-cross-council-initiative/ (2016). O'Neill, J. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations (2016). Transatlantic Taskforce on Antimicrobial Resistance. Recommendations for future collaboration between the US and EU, Atlanta US, 1–86, https://www.cdc.gov/drugresistance/pdf/tatfar-progress_report_2014.pdf (2014). RexJHA comprehensive regulatory framework to address the unmet need for new antibacterial treatmentsLancet Infect Dis.20131326927510.1016/S1473-3099(12)70293-123332713 MendelsonMA global antimicrobial conservation fund for low- and middle-income countriesInt. J. Infect. Dis.201651707210.1016/j.ijid.2016.09.01627647658 Newton Fund. http://www.newtonfund.ac.uk (2017). Office of the Press Secretary, The White House. Executive Order No. 13676 — Combating Antibiotic-Resistant Bacteria (2014). RCUK Global Challenge Research Fund http://www.rcuk.ac.uk/funding/gcrf/ (2017). BEAM Alliance. BEAM Alliance position paper: key actions to reinvigorate investment and R&D in the antibacterial field now, Paris FR, 1–9, https://beam-alliance.eu/assets/2015-Position-Paper.pdf (2015). OuttersonKAccelerating global innovation to address antibacterial resistance: introducing CARB-XNat. Rev. Drug Discov.2016155895901:CAS:528:DC%2BC28Xht1GisbzM10.1038/nrd.2016.15527469032 ButlerMSBlaskovichMACooperMAAntibiotics in the clinical pipeline in 2013J. Antibiot. (Tokyo)2013665715911:CAS:528:DC%2BC3sXhs1yiu7vP10.1038/ja.2013.86 The Review on Antimicrobial Resistance. Antimicrobial resistance: tackling a crisis for the health and wealth of nations, London UK, 1–20, https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf (2014). JH Rex (BFja2017124_CR2) 2013; 13 B Spellberg (BFja2017124_CR4) 2014; 18 JK Billington (BFja2017124_CR34) 2015; 13 S Stern (BFja2017124_CR7) 2017 BFja2017124_CR41 DM Brogan (BFja2017124_CR49) 2013; 9 BFja2017124_CR40 BFja2017124_CR44 BFja2017124_CR43 BFja2017124_CR42 BFja2017124_CR48 MJ Eichberg (BFja2017124_CR35) 2015; 13 E Mossialos (BFja2017124_CR45) 2010 BFja2017124_CR39 JH Rex (BFja2017124_CR50) 2016; 16 I Chopra (BFja2017124_CR10) 2008; 8 T Kostyanev (BFja2017124_CR29) 2015; 15 BFja2017124_CR51 BFja2017124_CR11 DL Monnet (BFja2017124_CR46) 2005; 17 BFja2017124_CR53 BFja2017124_CR16 SJ Hoffman (BFja2017124_CR52) 2015; 93 BFja2017124_CR14 BFja2017124_CR13 T Kostyanev (BFja2017124_CR30) 2016; 71 MJ Renwick (BFja2017124_CR15) 2016; 69 BFja2017124_CR6 M Mendelson (BFja2017124_CR12) 2016; 51 BFja2017124_CR8 BFja2017124_CR5 A Kesselheim (BFja2017124_CR54) 2013; 11 BFja2017124_CR23 BFja2017124_CR22 R Kelly (BFja2017124_CR27) 2016; 16 BFja2017124_CR1 BFja2017124_CR21 BFja2017124_CR26 BFja2017124_CR25 BFja2017124_CR24 JS Ferraro (BFja2017124_CR47) 2017 BFja2017124_CR19 BFja2017124_CR18 BFja2017124_CR17 DM Brogan (BFja2017124_CR33) 2016; 12 BFja2017124_CR32 K Outterson (BFja2017124_CR20) 2016; 15 BFja2017124_CR31 BFja2017124_CR38 BFja2017124_CR37 BFja2017124_CR36 MS Butler (BFja2017124_CR9) 2013; 66 K Outterson (BFja2017124_CR3) 2015; 34 BFja2017124_CR28 |
| References_xml | – reference: CARB-X.. CARB-X injects up to $48 million to accelerate first powered by CARB-X portfolio of drug discovery and development projects to tackle antibiotic resistance, http://www.carb-x.org/press (2017). – reference: Political Declaration of the high-level meeting of the General Assembly on antimicrobial resistance http://www.un.org/ga/search/view_doc.asp?symbol=A/71/L.2&referer=/english/&Lang=E (2016). – reference: BillingtonJKThe ABCs of the US Broad Spectrum Antimicrobials Program: antibiotics, biosecurity, and congressHealth Secur.20151334935410.1089/hs.2015.0034265693794685490 – reference: Office of the Assistant Secretary of Preparedness and Response. HHS forms strategic alliance to develop new antibiotics approach provides a pipeline of new drugs rather than a single medical countermeasure. US Department of Health and Human Services, http://www.phe.gov/Preparedness/news/Pages/strategic-alliance-130522.aspx (2013). – reference: The Boston Consulting Group. Breaking through the wall: enhancing research and development of antibiotics in science and industry, Berlin DE, 1–84, https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/5_Publikationen/Gesundheit/Berichte/GUARD_Follow_Up_Report_Full_Report_final.pdf (2017). – reference: HoffmanSJStrategies for achieving global collective action on antimicrobial resistanceBull. World Health Organ20159386787610.2471/BLT.15.153171266684394669731 – reference: EichbergMJPublic funding of clinical-stage antibiotic development in the United States and European UnionHealth Secur.20151315616510.1089/hs.2014.0081260428594486734 – reference: MonnetDLAntibiotic development and the changing role of the pharmaceutical industryInt. J. Risk Saf. Med.200517133145 – reference: European Investment Bank. InnovFin Infectious Disease, http://www.eib.org/attachments/documents/innovfin_infectious_diseases_flysheet_en.pdf (2015). – reference: SternSC.SFrankenLVollerSRentmeisterHGroschBA Call for Concerted Action on Antibiotics Research and evelopment2017The Boston Consulting Group, Berlin – reference: Antibiotics Currently in Clinical Development http://www.pewtrusts.org/~/media/assets/2017/05/antibiotics-currently-in-clinical-development-03-2017.pdf?la=en (2017). – reference: Joint Programming Initiative on Antimicrobial Resistance, http://www.jpiamr.eu (2017). – reference: Pew Charitable Trusts. GAIN: how a new law is stimulating the development of antibiotics http://www.pewtrusts.org/en/research-and-analysis/issue-briefs/2013/11/07/gain-how-a-new-law-is-stimulating-the-development-of-antibiotics/ (2013). – reference: KesselheimAOuttersonKImproving antibiotic markets for long term sustainabilityYale J. Health Pol. Law Ethics201311101168 – reference: Renwick, M. J., Simpkin, V. & Mossialos, E. Targeting innovation in antibiotic drug discovery and development: the need for a one-health, one-Europe, one-world framwork. European Observatory on Health Systems and Policies, London, UK, Health Policy Series No. 45, 1–133, ISBN 9789289050401 (2016). – reference: The Review on Antimicrobial Resistance. Tackling a global health crisis: initial steps, London UK, 1–22, https://amr-review.org/sites/default/files/Report-52.15.pdf (2015). – reference: BEAM Alliance. BEAM Alliance position paper: key actions to reinvigorate investment and R&D in the antibacterial field now, Paris FR, 1–9, https://beam-alliance.eu/assets/2015-Position-Paper.pdf (2015). – reference: O'Neill, J. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations (2016). – reference: The Review on Antimicrobial Resistance. Antimicrobial resistance: tackling a crisis for the health and wealth of nations, London UK, 1–20, https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf (2014). – reference: SpellbergBThe future of antibioticsCrit. Care20141822810.1186/cc13948250439624075146 – reference: Global Antibiotic Research & Development Partnership (GARDP), http://www.dndi.org/diseases-projects/gardp/ (2017). – reference: MendelsonMA global antimicrobial conservation fund for low- and middle-income countriesInt. J. Infect. Dis.201651707210.1016/j.ijid.2016.09.01627647658 – reference: Newton Fund. http://www.newtonfund.ac.uk (2017). – reference: European and Developing Countries Clinical Trials Partnership. Annual Report 2014, The Hague NL, 1–76, http://www.edctp.org/annualreport2014/EDCTP_Annual_Report_2014_-_EN.pdf (2014). – reference: UK-China ties flourish at 2016 High Level People to People Dialogue, https://www.gov.uk/government/news/uk-china-ties-flourish-at-2016-high-level-people-to-people-dialogue (2016). – reference: KostyanevTBontenMJO'BrienSGoossensHInnovative medicines initiative and antibiotic resistanceLancet Infect. Dis.2015151373137510.1016/S1473-3099(15)00407-726607115 – reference: US Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013, Atlanta US, 1–114, https://www.cdc.gov/drugresistance/threat-report-2013/index.html (2013). – reference: RCUK Global Challenge Research Fund http://www.rcuk.ac.uk/funding/gcrf/ (2017). – reference: RexJHOuttersonKAntibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approachLancet Infect. Dis.20161650050510.1016/S1473-3099(15)00500-927036356 – reference: OuttersonKPowersJHDanielGWMcClellanMBRepairing the broken market for antibiotic innovationHealth Aff. (Millwood)20153427728510.1377/hlthaff.2014.1003 – reference: EC. Better use of antibiotics-1 million euros, http://ec.europa.eu/research/horizonprize/index.cfm?prize=better-use-antibiotics (2017). – reference: KostyanevTThe innovative medicines initiative's new drugs for bad bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistanceJ. Antimicrob. Chemother.2016712902951:CAS:528:DC%2BC28Xjs1Ohsr8%3D10.1093/jac/dkv33926568581 – reference: ChopraITreatment of health-care-associated infections caused by Gram-negative bacteria: a consensus statementLancet Infect. Dis.2008813313910.1016/S1473-3099(08)70018-518222164 – reference: Interagency Coordination Group on Antimicrobial Resistance. https://www.un.org/sg/en/content/sg/personnel-appointments/2017-03-17/interagency-coordination-group-antimicrobial-resistance (2017). – reference: KellyRZoubianeGWalshDWardRGoossensHPublic funding for research on antibacterial resistance in the JPIAMR countries, the European Commission, and related European Union agencies: a systematic observational analysisLancet Infect. Dis.20161643144010.1016/S1473-3099(15)00350-3267085244802226 – reference: RenwickMJBroganDMMossialosEA systematic review and critical assessment of incentive strategies for discovery and development of novel antibioticsJ. Antibiot. (Tokyo)20166973881:CAS:528:DC%2BC28Xjt1Oku78%3D10.1038/ja.2015.98 – reference: Drive-AB Official Website, http://drive-ab.eu/. – reference: MossialosEEdwardsMCBerensonSGemmill-ToyamaJBroganMDPolicies and Incentives for Promoting Innovation in Antibiotic Research2010World Health Organisation – reference: First Joint Call: innovative approaches to address antibacterial resistance http://www.jpiamr.eu/activities/joint-calls/first-joint-callresult/ (2014). – reference: Pew Charitable Trusts. LPAD: a regulatory pathway to develop antibiotics and fight drug-resistant infections http://www.pewtrusts.org/en/research-and-analysis/q-and-a/2015/06/lpad-a-regulatory-pathway-to-develop-antibiotics-and-fight-drug-resistant-infections (2015). – reference: EC. Antimicrobial drug resistance https://ec.europa.eu/research/health/index.cfm?pg=area&areaname=amdr (2017). – reference: ButlerMSBlaskovichMACooperMAAntibiotics in the clinical pipeline in 2013J. Antibiot. (Tokyo)2013665715911:CAS:528:DC%2BC3sXhs1yiu7vP10.1038/ja.2013.86 – reference: BroganDMMossialosEA critical analysis of the review on antimicrobial resistance report and the infectious disease financing facilityGlobal Health201612810.1186/s12992-016-0147-y270008474802890 – reference: Transatlantic Taskforce on Antimicrobial Resistance. Recommendations for future collaboration between the US and EU, Atlanta US, 1–86, https://www.cdc.gov/drugresistance/pdf/tatfar-progress_report_2014.pdf (2014). – reference: National Institute for Health Research. Antimicrobial resistance http://www.nihr.ac.uk/research-and-impact/research-priorities/antimicrobial-resistance.htm. – reference: Office of the Press Secretary, The White House. Executive Order No. 13676 — Combating Antibiotic-Resistant Bacteria (2014). – reference: WHO Global Priority List of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics 1–7 World Health Organisation, (2017). – reference: FerraroJSTowseAMestre-FerrandizJIncentives for New Drugs to Tackle Anti-Microbial Resistance2017Office of Health Economics – reference: BroganDMMossialosEIncentives for new antibiotics: the Options Market for Antibiotics (OMA) modelGlobal Health201395810.1186/1744-8603-9-58241998354226193 – reference: RexJHA comprehensive regulatory framework to address the unmet need for new antibacterial treatmentsLancet Infect Dis.20131326927510.1016/S1473-3099(12)70293-123332713 – reference: The Review on Antimicrobial Resistance. Securing new drugs for future generations: the pipeline of antibiotics, London UK, 1–44, https://amr-review.org/sites/default/files/SECURING%20NEW%20DRUGS%20FOR%20FUTURE%20GENERATIONS%20FINAL%20WEB_0.pdf (2015). – reference: MRC Tackling AMR-a cross-council initiative. https://www.mrc.ac.uk/research/initiatives/antimicrobial-resistance/tackling-amr-a-cross-council-initiative/ (2016). – reference: OuttersonKAccelerating global innovation to address antibacterial resistance: introducing CARB-XNat. Rev. Drug Discov.2016155895901:CAS:528:DC%2BC28Xht1GisbzM10.1038/nrd.2016.15527469032 – reference: CARB-X, http://www.carb-x.org (2017). – ident: BFja2017124_CR17 – ident: BFja2017124_CR42 – volume: 13 start-page: 156 year: 2015 ident: BFja2017124_CR35 publication-title: Health Secur. doi: 10.1089/hs.2014.0081 – ident: BFja2017124_CR6 – ident: BFja2017124_CR23 – volume: 8 start-page: 133 year: 2008 ident: BFja2017124_CR10 publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(08)70018-5 – volume: 12 start-page: 8 year: 2016 ident: BFja2017124_CR33 publication-title: Global Health doi: 10.1186/s12992-016-0147-y – volume: 93 start-page: 867 year: 2015 ident: BFja2017124_CR52 publication-title: Bull. World Health Organ doi: 10.2471/BLT.15.153171 – ident: BFja2017124_CR32 – volume: 69 start-page: 73 year: 2016 ident: BFja2017124_CR15 publication-title: J. Antibiot. (Tokyo) doi: 10.1038/ja.2015.98 – ident: BFja2017124_CR51 – volume: 17 start-page: 133 year: 2005 ident: BFja2017124_CR46 publication-title: Int. J. Risk Saf. Med. doi: 10.3233/JRS-2005-349 – ident: BFja2017124_CR36 – ident: BFja2017124_CR13 – volume: 15 start-page: 589 year: 2016 ident: BFja2017124_CR20 publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd.2016.155 – ident: BFja2017124_CR18 – ident: BFja2017124_CR41 – ident: BFja2017124_CR39 – volume: 18 start-page: 228 year: 2014 ident: BFja2017124_CR4 publication-title: Crit. Care doi: 10.1186/cc13948 – ident: BFja2017124_CR24 – ident: BFja2017124_CR5 – ident: BFja2017124_CR1 – ident: BFja2017124_CR31 – ident: BFja2017124_CR28 – volume-title: Policies and Incentives for Promoting Innovation in Antibiotic Research year: 2010 ident: BFja2017124_CR45 – ident: BFja2017124_CR14 – volume: 51 start-page: 70 year: 2016 ident: BFja2017124_CR12 publication-title: Int. J. Infect. Dis. doi: 10.1016/j.ijid.2016.09.016 – volume: 15 start-page: 1373 year: 2015 ident: BFja2017124_CR29 publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(15)00407-7 – volume: 71 start-page: 290 year: 2016 ident: BFja2017124_CR30 publication-title: J. Antimicrob. Chemother. doi: 10.1093/jac/dkv339 – volume: 16 start-page: 500 year: 2016 ident: BFja2017124_CR50 publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(15)00500-9 – ident: BFja2017124_CR40 – ident: BFja2017124_CR8 – ident: BFja2017124_CR19 – ident: BFja2017124_CR44 – ident: BFja2017124_CR38 – volume: 13 start-page: 269 year: 2013 ident: BFja2017124_CR2 publication-title: Lancet Infect Dis. doi: 10.1016/S1473-3099(12)70293-1 – ident: BFja2017124_CR25 – ident: BFja2017124_CR21 – volume: 9 start-page: 58 year: 2013 ident: BFja2017124_CR49 publication-title: Global Health doi: 10.1186/1744-8603-9-58 – ident: BFja2017124_CR53 – ident: BFja2017124_CR48 – ident: BFja2017124_CR11 – volume: 11 start-page: 101 year: 2013 ident: BFja2017124_CR54 publication-title: Yale J. Health Pol. Law Ethics – volume-title: Incentives for New Drugs to Tackle Anti-Microbial Resistance year: 2017 ident: BFja2017124_CR47 – ident: BFja2017124_CR43 – ident: BFja2017124_CR16 – volume: 66 start-page: 571 year: 2013 ident: BFja2017124_CR9 publication-title: J. Antibiot. (Tokyo) doi: 10.1038/ja.2013.86 – ident: BFja2017124_CR37 – volume: 34 start-page: 277 year: 2015 ident: BFja2017124_CR3 publication-title: Health Aff. (Millwood) doi: 10.1377/hlthaff.2014.1003 – ident: BFja2017124_CR22 – volume: 16 start-page: 431 year: 2016 ident: BFja2017124_CR27 publication-title: Lancet Infect. Dis. doi: 10.1016/S1473-3099(15)00350-3 – volume: 13 start-page: 349 year: 2015 ident: BFja2017124_CR34 publication-title: Health Secur. doi: 10.1089/hs.2015.0034 – ident: BFja2017124_CR26 – volume-title: A Call for Concerted Action on Antibiotics Research and evelopment year: 2017 ident: BFja2017124_CR7 |
| SSID | ssj0037378 |
| Score | 2.5685174 |
| SecondaryResourceType | review_article |
| Snippet | Political momentum and funding for combatting antimicrobial resistance (AMR) continues to build. Numerous major international and national initiatives aimed at... |
| SourceID | pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1087 |
| SubjectTerms | 692/700 692/700/155 Antibiotics Bacteriology Biomedical and Life Sciences Bioorganic Chemistry Funding Life Sciences Literature reviews Medicinal Chemistry Microbiology Organic Chemistry Pharmaceutical industry Public health R&D Research & development Review review-article |
| Title | Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps |
| URI | https://link.springer.com/article/10.1038/ja.2017.124 https://www.ncbi.nlm.nih.gov/pubmed/29089600 https://www.proquest.com/docview/1978701929 https://www.proquest.com/docview/1958542073 https://pubmed.ncbi.nlm.nih.gov/PMC5746591 |
| Volume | 70 |
| WOSCitedRecordID | wos000418362200002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1881-1469 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0037378 issn: 0021-8820 databaseCode: M7P dateStart: 20050101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1881-1469 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0037378 issn: 0021-8820 databaseCode: 7X7 dateStart: 20050101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1881-1469 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0037378 issn: 0021-8820 databaseCode: BENPR dateStart: 20050101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 1881-1469 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0037378 issn: 0021-8820 databaseCode: M2P dateStart: 20050101 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwEB6xuxyQEI_lFVgqIy17QA2bxHHscEGAdsWFKkI99Bb5lSUVSkvTIvXf48mrlCIuXKJEHiWOZjye8cx8A3BOQ8YDUQjfKMmdg2KML3VofEWZchIljAjaZhN8MhGzWZp1B251l1bZ68RGUZuFxjPyyzBF0XL2SPp--cPHrlEYXe1aaBzBCaIk0CZ1L-s1MeW008RR6DtLMujq8wIqLueIORTyt2EU7-9IB2bmYbbkHyHTZie6vv-___AA7nU2KPnQCs1DuGWrU7jIWhDr7ZhMdzVZ9ZhckGwHb709hbvtSR9pC5gewdypGEw5wir16oaUQ5tVd0sc30pVLtybiFltbggWAWPS6NaNGGJ2GUvvSJMp5vTumOi-wUvdUFVu_yBOGJf1Y5heX00_ffa7Dg6-ZjRZ-yY0kmurVGwL55cVkUb3T3GRmMjogstUFkEaKI3ltgjdz3XKCi4olbGNLH0Cx9Wiss-ARMLG0jIbx0USq1RIZhlL4oAqTpWWqQdveibmukM3xyYb3_Mmyk5FPpc5cjx3HPfgfCBetqAefyc769mYdyu7znc89ODVMOzWJAZaZGUXG6RxTlgcOVn34GkrPMN3Igy0OivTA74nVgMB4n3vj1Tltwb3m_E4YWnoweteAH-b1uH0n_97-i_gDlK2qTlncLxebexLuK1_rst6NYIjPuPNVYzg5OPVJPvqnr5E2ahZYr8Ax0cuMA |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB6VggQS4lFehgKL1PZQxdTetb1rJIQQULVqiXLIoTdrXy6OkBPiBJQfxX9k1o-EEMStB26Wdmyv7G9mZ3a_mQHYY2HMA5EL3yjJMUAxxpc6NL5isUJECSOCptkE7_fFxUU62IKfXS6Mo1V2NrE21Gas3R75UZg6aKE_kr6bfPNd1yh3utq10GhgcWYXPzBkq96efsT_u0_p8afhhxO_7Srg65glM9-ERnJtlYpsjrFCTrULSRQXiaFG51ymMg_SQGmXAurKyXOdxjkXjMnIUsvwsdfgOnoRVNRMwUFn-BlnreGnoY-Oa9CmAwZMHI1ciaOQvw5ptL4Abni1m-TMP05o64Xv-O5_9snuwZ3WwybvG5W4D1u23IGDQVOie9Ejw1XGWdUjB2SwKt692IHbzT4madKzHsAIDagjVLkc_PKSFMsmsnhJEJWFKsb4JGKm80viUpwdJXaBI4aYFR_rDal5cLiq9Iju2tdUtVSJqyNBVZtUD2F4FZ_lEWyX49I-AUKFjaSNbRTlSaRSIWMbx0kUMMWZ0jL14LDDTKbb2u2uhcjXrOYQMJGNZOYAliHAPNhbCk-akiV_F9vtUJO1dqvKVpDx4NVyGC2OO0aSpR3PnQyGmBFFTfbgcYPV5XuoO0ZGH9oDvobipYCrZr4-UhZf6qrmMY-SOA092O_w_tu0Nqf_9N_Tfwk3T4afz7Pz0_7ZM7jl7mpISLuwPZvO7XO4ob_Pimr6otZhAtkVK8AvQs2G4w |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB6VghAS4lFehgKL1PZQxcT22tk1EkKIElEVRTn00Ju1L5dEyAlxAspP498x40dCCOLWA7dIO3FWm29e3m9mAA54mIhA5tK3WglMUKz1lQmtr3miEVHSyqAeNiEGA3lxkQ534GdbC0O0ytYmVobaTgy9I--GKUEL45G0mze0iOFJ_930m08TpOimtR2nUUPkzC1_YPpWvj09wf_6MIr6H88_fPKbCQO-SXhv7tvQKmGc1rHLMW_II0PpiRayZyNrcqFSlQdpoA2Vg1JreWHSJBeScxW7yHF87DW4LqhnecUaHLZOgAveOIEo9DGIDZrSwIDL7pjaHYXidRjFm85wK8LdJmr-cVtbOcH-3f_4-O7BnSbyZu9rVbkPO67Yg6Nh3bp72WHn60q0ssOO2HDd1Hu5B7fr95usLtt6AGM0rES0otr84pKNVsNl8SNDtI70aIJPYna2uGRU-kxU2SWuWGbXPK03rOLHobfpMNOOtSkrqQLPjqEKTsuHcH4Vx_IIdotJ4Z4Ai6SLlUtcHOe9WKdSJS5JenHAteDaqNSD4xY_mWl6utNoka9ZxS3gMhurjMCWIdg8OFgJT-tWJn8X228RlDX2rMzW8PHg1WoZLRFdL6nCTRYkg6lnHKGGe_C4xu3qdyK6XsbY2gOxgeiVAHU531wpRl-qbucJqleShh4cttj_bVvb23_67-2_hJuI--zz6eDsGdyiL9XcpH3Ync8W7jncMN_no3L2olJnBtkV4_8XG0-PoA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Incentivising+innovation+in+antibiotic+drug+discovery+and+development%3A+progress%2C+challenges+and+next+steps&rft.jtitle=Journal+of+antibiotics&rft.au=Simpkin%2C+Victoria+L&rft.au=Renwick%2C+Matthew+J&rft.au=Kelly%2C+Ruth&rft.au=Mossialos%2C+Elias&rft.date=2017-12-01&rft.pub=Nature+Publishing+Group+UK&rft.issn=0021-8820&rft.eissn=1881-1469&rft.volume=70&rft.issue=12&rft.spage=1087&rft.epage=1096&rft_id=info:doi/10.1038%2Fja.2017.124&rft.externalDocID=10_1038_ja_2017_124 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-8820&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-8820&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-8820&client=summon |